

AXIRON NET SALES, QUARTER TO 30 JUNE 2016

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company* reported global Axiron net sales of US\$29.3 million in its financial results for the quarter ending 30 June 2016, down from US\$32.4 million for the previous corresponding quarter to 30 June, 2015.

Axiron net sales for the financial year 2016 are shown in the following table:

Q3 2014	Q4 2014	Q1 2015	Q2 2015	Total FY 2015
US\$36.3m	US\$47.6m	US\$39.1m	US\$32.4m	US\$155.4m
Q3 2015	Q4 2015	Q1 2016	Q2 2016	Total FY 2016
US\$41.4m	US\$41.6m	US\$37.0m	US\$29.3m	US\$149.3m

Based on IMS data, the total number of prescriptions in the US for Axiron in the financial year 2016 declined by 10.8% when compared to the same time period of time in the financial year 2015, while US reported net sales declined by 3.2% for the same period. Axiron holds a US market share of 14.2%, slightly higher than that of June 2015 at 14.0%.

**Eli Lilly and Company is the global licensee of Axiron*

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit www.acrux.com.au

